Method for treating ocular neovascular diseases

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S912000

Reexamination Certificate

active

06271233

ABSTRACT:

The invention relates to new phthalazine derivatives for the manufacture of a pharmaceutical preparation for the treatment and prevention of ocular neovascular diseases. It further relates to the treatment and prevention of such ocular diseases the phthalazine derivatives.
BACKGROUND OF THE INVENTION
Two processes, the de novo formation of vessels from differentiating endothelial cells or angioblasts in the developing embryo (vasculogenesis) and the growth of new capillary vessels from existing blood vessels (angiogenesis), are involved in the development of the vascular systems of animal organs and tissues.
Recent findings show that at the centre of the network regulating the growth and differentiation of the vascular system and its components, both during embryonic development and normal growth and in a wide number of pathological anomalies and diseases, lies the angiogenic factor known as “Vascular Endothelial Growth Factor” (=VEGF), along with its cellular receptors. (see, Breier, et al.,
Trends in Cell Biology
6: 454-456, 1996).
VEGF receptors are transmembrane receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain. Various types of VEGF receptor are known, e.g. VEGFR-1, VEGFR-2, and VEGFR-3.
SUMMARY OF THE INVENTION
It has now been found that phthalazine derivatives of formula I, described below, have advantageous pharmacological properties and inhibit ocular neovascularization, including retinal neovascularization and choroidal neovascularization.


REFERENCES:
patent: 03106875 A2 (1991-05-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO 97/34920 (1997-09-01), None
patent: WO 97/40831 (1997-11-01), None
patent: WO 98/35958 (1998-08-01), None
Chemical Abstracts, 69 : 19180. Parsons et al., 1965.*
European Patent Office Standard Search Report.
The 23rd German Cancer conference, Berlin 8-12 Jun. 1998, Germany Needs Interdisciplinary Approach to Cancer Research, International Cancer News, Jun. 8, 1998, pp. 1474-1475.
Protein Kinase C. Activation and Its Role in the Development of Vascular Compliclations in Diabetes Mellitus, Hidehiro Ishii, et al.
Pharmazeutische Zeitung, Christiane Berg vol. 34, 1998, pp. 1474-1475.
Proceedings of the American Association for Cancer Research, J. Wood, et al, Vo.. 39, Mar. 1998, pp. 96.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for treating ocular neovascular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treating ocular neovascular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating ocular neovascular diseases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2434999

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.